THURSDAY, Nov. 12 (HealthDay News) -- A drug for people with a form of leukemia holds promise as a possible treatment for ovarian cancer, new research suggests.
The drug dasatinib (Sprycel) is used to treat chronic myeloid leukemia. Researchers at the University of California at Los Angeles report that the drug limited the growth and invasive powers of ovarian cancer cells.
It also proved to have even more cancer-fighting powers when it was combined with chemotherapy and used to fight certain kinds of ovarian cancer cells known as Src dependent, according to the report published in the Nov. 10 issue of the BMJ.
Ovarian cancer is the most deadly cancer that strikes the female reproductive system and is expected to kill 15,500 women in the United States this year. The cancer is very difficult to treat.
"It is important to remember that this work is only on cancer cell lines, but it is significant enough that it should be used to justify clinical trials to confirm that women with this type of ovarian cancer could benefit," Gottfried Konecny, an assistant professor of hematology/oncology and first author of the study, said in a UCLA news release.
An estimated one-third of women with ovarian cancer have the type known as Src dependent.
"We were able to identify markers in the pre-clinical setting that would allow us to predict response to Sprycel," Konecny said. "These may help us in future clinical trials in selecting patients for studies of the drug."
More information
Learn more about ovarian cancer from the U.S. National Cancer Institute.
TUESDAY, Nov. 10 (HealthDay News) -- Even three years after finishing treatment for breast cancer, almost 50 percent of women report long-term pain, a new Danish study finds.
The research, published in the Nov. 11 issue of the Journal of the American Medical Association, strengthens earlier findings, said study senior author Dr. Henrik Kehlet, a professor of perioperative therapy at Rigshospitalet at Copenhagen University. But this work indicates which women are most likely to experience persistent pain.
"Several previous scientific reports have shown a risk of chronic pain after breast cancer surgery," said Kehlet. The strength of this study, he noted, is the large number of participants -- more than 3,000 -- and the evaluation of many types of treatments.
Kehlet's team reviewed questionnaires filled out by 3,253 women who had undergone breast cancer treatment in Denmark between 2005 and 2006. Their treatments varied and included breast-conserving surgery, mastectomy, radiation, chemotherapy and dissection of the lymph nodes.
The women were asked whether they experienced pain, in what areas of the body, how bad it was and how often they experienced it.
In all, 1,543 -- 47 percent -- reported pain in one or more areas. Of those, 52 percent reported severe or moderate pain.
Among those who had severe pain, 77 percent said they had it daily. For those who reported their pain as light, 36 percent had it every day. Pain was reported in the breast area, the armpit, the arm and the side of the body.
The research was funded by the Danish Cancer Society, Breast Friends and a private organization that funds science research, the Lundbeck Foundation.
Women under 40 were more than three times more likely to have chronic pain than older women, the researchers found. Those having radiation therapy were more likely to have pain than those who had chemotherapy. Dissection of the axillary (under arm) lymph node was associated with increased likelihood of pain compared to dissection of the sentinel lymph node (the first node to which the cancer is likely to spread).
Why does the pain linger?
"There are multiple mechanisms to explain the risk of chronic pain," Kehlet said, "such as young age, risk of nerve damage during axillary dissection, radiation therapy or a general pain hyper-responsiveness in some patients."
More research is needed on the pain mechanism in those who experience high levels of discomfort, he said. The focus for now should be on identifying patients at high risk for pain and providing preventive treatment and nerve-sparing treatment when possible.
The results do not surprise Dr. Robert H. Dworkin, a pain specialist and professor of anesthesiology, neurology, oncology and psychiatry at the University of Rochester School of Medicine and Dentistry in New York, who has also published on lingering cancer pain.
But the findings may come as a surprise to oncologists and others who treat cancer patients, he said. "Women tend not to tell their surgeons about this continuing pain," he said, citing clinical experience. Why? "They fear that the fact they are in pain might mean a recurrence, and they don't want to deal with it," he said. Or, "they don't want to hurt the oncologist's feelings."
A third reason is "they don't want to distract the physician from thinking about the cancer," he said.
Even pain specialists can't say for sure why the pain lingers. "We have little understanding of what causes this kind of pain," Dworkin said.
A woman in pain after breast cancer treatment "should not be shy in talking to her physician about it," Dworkin said. He advises such women to ask for a referral to a pain specialist.
More information
To learn more about pain control, visit the American Cancer Society. 
MONDAY, Nov. 9 (HealthDay News) -- Pregnant women who are depressed may suffer severe symptoms if they catch seasonal flu, a new study suggests.
Ohio State University researchers assessed depressive symptoms and took blood samples from 22 pregnant women before they received a seasonal flu shot. Those with significant symptoms of depression had a stronger inflammatory response to the flu shot than the other women.
This finding suggests that a depressed pregnant woman's immune system doesn't function normally, which means they may experience more serious symptoms if they're infected with seasonal flu.
"Inflammatory responses to vaccination do no harm, are mild, and typically go away within a few days. But an extended inflammatory response to vaccination, such as the one seen in women with the most depressive symptoms, isn't expected, and it serves as a way to estimate how somebody might respond to an actual infection or illness," lead author Lisa Christian, an assistant professor of psychiatry, said in a university news release.
The researchers said their study shows the need for pregnant women to get seasonal flu shots. The study was published online in advance of publication in the November print issue of the journal Brain, Behavior, and Immunity.
Public health groups advise pregnant women to get seasonal flu shots, but only 12 percent to 13 percent of them have done so in recent years, according to the U.S. Centers for Disease Control and Prevention.
"It will be interesting to see how that might change this year," in light of CDC recommendations that pregnant women receive both seasonal and H1N1 flu vaccinations, Christian said.
More information
The U.S. Centers for Disease Control and Prevention has more about seasonal flu.